Health
Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
PRINCETON, N.J., November 03, 2025--Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/bbe752f41c3f31f732fb21b14fc2e75e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a8yhu8d8_h1ybGPTklfCHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bbe752f41c3f31f732fb21b14fc2e75e","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/vpPp1T76nlhGwKx7umuI1g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/bbe752f41c3f31f732fb21b14fc2e75e","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Multiple real-world analyses and an analysis of long-term extension data reinforce the well-established efficacy and safety profile of Camzyos (mavacamten) in symptomatic obstructive hypertrophic cardiomyopathy","length":210,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., November 03, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data from its cardiovascular portfolio at the American Heart Association’s Scientific Sessions 2025, taking place November 7–10, 2025 in New Orleans, Louisiana. New analyses include results from a long-term extension study and real-world evidence that reinforce how Camzyos (mavacamten) has elevated the standard of treatment for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), as well as data on behalf of the BMS-Johnson & Johnson Collaboration on milvexian.","length":598,"tagName":"p"},{"type":"text","content":""Building on our 70-year legacy of cardiovascular innovation, Camzyos has reset the baseline for treating adults with symptomatic oHCM, allowing physicians and patients to move beyond symptom management to a treatment that has consistently demonstrated an ability to significantly reduce obstruction, impact cardiac structure, and improve symptoms," said Cristian Massacesi, MD, executive vice president, Chief Medical Officer and Head of Development, Bristol Myers Squibb. "The new data we are presenting at the American Heart Association’s Scientific Sessions 2025 highlight the consistent and sustained results we’ve seen in our long-term extension study over nearly four yea...